. 2020 Jan 29;77(6):1–11. doi: 10.1001/jamapsychiatry.2019.4693

Table 2. Mean Group Differences and Effect Sizes for Primary and Secondary Outcomes.

Measure	Within-Group Difference, Mean (SE)			Between-Group Effect Size, Cohen d (95% CI)
Measure	MMB Plus UDC Group	UDC Group	Difference	Between-Group Effect Size, Cohen d (95% CI)
PHQ-9 score
Total	−2.65 (0.29)^a	−1.70 (0.27)^a	0.95 (0.39)^b	0.23 (0.04 to 0.41)
Intervention phase	−2.83 (0.24)^a	−0.94 (0.22)^a	1.89 (0.32)^a	0.55 (0.36 to 0.73)
Follow-up phase	0.19 (0.26)	−0.76 (0.24)^c	−0.95 (0.35)^c	−0.25 (−0.44 to –0.07)
PHQ-9 remission (PHQ-9, ≤5)
Total	1.23 (0.11)^a	0.86 (0.10)^a	−0.37 (0.12)^c	−0.28 (−0.46 to –0.09)
Intervention phase	1.16 (0.12)^a	0.37 (0.12)^c	−0.79 (0.14)^a	−0.55 (−0.73 to –0.36)
Follow-up phase	0.07 (0.10)	0.49 (0.10)^a	0.42 (0.14)^c	0.28 (0.10 to 0.47)
GAD-7 score
Total	−2.48 (0.31)^a	−1.27 (0.29)^a	1.21 (0.42)^c	0.27 (0.09 to 0.45)
Intervention phase	−2.34 (0.28)^a	−0.75 (0.26)^c	1.60 (0.37)^a	0.40 (0.22 to 0.59)
Follow-up phase	−0.14 (0.30)	−0.53 (0.27)	−0.39 (0.40)	−0.09 (−0.27 to 0.09)
SF-12 score (PCS)
Total	−1.86 (0.68)^c	−2.39 (0.63)^c	−0.53 (0.93)	−0.12 (−0.30 to 0.06)
Intervention phase	−1.64 (0.57)^c	−2.38 (0.53)^a	−0.74 (0.78)	−0.06 (−0.24 to 0.12)
Follow-up phase	−0.22 (0.69)	−0.003 (0.64)	0.22 (0.94)	−0.05 (−0.23 to 0.13)
SF-12 score (MCS)
Total	10.27 (1.01)^a	5.17 (0.93)^a	−5.10 (1.37)^c	0.45 (0.26 to 0.63)
Intervention phase	9.78 (0.81)^a	4.11 (0.76)^a	−5.67 (1.11)^a	0.54 (0.35 to 0.73)
Follow-up phase	0.49 (0.98)	1.06 (0.90)	0.57 (1.33)	0.05 (−0.13 to 0.23)
Total depression-free days^d	281.43 (164.99)	247.46 (158.32)	−33.97 (149.66)^c	0.22 (0.04 to 0.40)

Abbreviations: GADS-7 indicates Generalized Anxiety Disorder–7; MCS, mental component summary; MMB, Mindful Mood Balance; PCS, physical component summary; PHQ-9, Patient Health Questionnaire–9; SF-12, 12-Item Short Form Survey; UDC, usual depression care.

^{^a}

P < .001.

^{^b}

P < .05.

^{^c}

P < .01.

^{^d}

Data are mean (SD) days.